Appili Therapeutics Inc Class A (TSE:APLI) has released an update.
Appili Therapeutics Inc., a biopharmaceutical company specializing in infectious disease treatments, has confirmed securing a C$300,000 bridge loan from Bloom Burton & Co. This funding, bearing a 10% annual interest rate, is earmarked for working capital and administrative needs, with repayment due by April 2025 or upon a change of the company’s control. The loan is part of a related party transaction under Canadian securities regulations, with the company seeking expedited completion for business reasons.
For further insights into TSE:APLI stock, check out TipRanks’ Stock Analysis page.
